Clinical Trials

106 enrolled 28 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05564390 2026-03-18

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Phase 2 Recruiting

2,000 enrolled

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05600894 2026-03-18

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

132 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT04227847 2026-03-16

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

178 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02392572 2026-03-12

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

120 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

30 enrolled

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03471260 2026-03-11

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

96 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

40 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03404193 2026-03-10

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Phase 2 Terminated

235 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06548230 2026-03-09

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

40 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03969446 2026-03-05

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

54 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07044544 2026-03-04

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

20 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05428969 2026-02-20

BEXMAB

181 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT04708054 2026-02-19

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Phase 2/3 Recruiting

324 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04655755 2026-02-18

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

52 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04160052 2026-02-12

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

51 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

16 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT07228273 2026-01-22

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Phase 2 Recruiting

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03661307 2026-01-12

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

73 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04550442 2026-01-12

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

34 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05342584 2026-01-08

Venetoclax AML

99 enrolled

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05184842 2026-01-05

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

Phase 2 Recruiting

91 enrolled 26 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03613532 2025-12-24

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05564650 2025-12-08

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

6 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Suspended

20 enrolled

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04937166 2025-11-10

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

25 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03113643 2025-11-04

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

72 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04874194 2025-11-03

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

24 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06419634 2025-10-30

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

105 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04581512 2025-10-14

Study to Evaluate the Safety and Tolerability of EP0042

70 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06563804 2025-10-14

A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

13 enrolled

Phase 2 Active not recruiting

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02250937 2025-10-06

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

116 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05168202 2025-09-25

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

56 enrolled 24 charts

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06501196 2025-09-24

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

170 enrolled

Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute

NCT07183878 2025-09-19

Ven-BUCY

Phase NA Recruiting

138 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04278768 2025-08-17

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

366 enrolled

Myelodysplastic Syndromes, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Leukemia, Myeloid, Acute

NCT02942290 2025-08-05

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

129 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04603001 2025-06-27

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

260 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02397720 2025-06-08

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Phase 2 Completed

150 enrolled 17 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

17 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04487106 2025-04-22

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Phase 2 Completed

21 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05766514 2025-04-22

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Phase 2 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04017546 2024-09-19

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Phase 1 Completed

14 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT03176277 2024-07-15

A Study of ONO-7475 in Patients With Acute Leukemias

42 enrolled 47 charts

Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06337331 2024-06-14

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Phase 2 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04912063 2024-02-26

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

40 enrolled

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT05107856 2024-01-31

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

21 enrolled